ReviewPharmaceutical medicine2026
Embracing Digital as a Paradigm Shift in Medical Affairs.
Review in Pharmaceutical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Digital transformation is increasingly shaping how the Medical Affairs (MA) function generates insights, engages stakeholders, and demonstrates value within the pharmaceutical industry. This article examines how MA professionals can navigate and lead the digital revolution reshaping healthcare delivery and stakeholder engagement. Digital maturity progresses from basic channel activation through tactical integration to advanced personalisation enabled by artificial intelligence (AI). Central to this transformation is the convergence of omnichannel engagement with real-world evidence generation, creating unprecedented opportunities to deliver personalised, scientifically rigorous interactions that enhance patient outcomes and healthcare professional (HCP) satisfaction. AI applications are creating new opportunities for MA to generate insights, communicate evidence, and measure impact across the healthcare ecosystem, enabling predictive analytics and intelligent content delivery at scale. Digital transformation is less likely to be effective when implemented through organisational silos. Important enablers include cross-functional collaboration, robust governance for responsible AI deployment, co-creation with external partners including HCPs and patient advocacy groups, and shared technology infrastructure that supports coordinated engagement. Best practices for digital communication strategies, fostering innovation cultures, and demonstrating measurable value are explored. As healthcare's digital evolution accelerates, MA has an important role in ensuring that digital tools are applied in ways that remain scientifically rigorous, ethically governed, and aligned with stakeholder needs. By treating digital as an enabler of high-quality scientific exchange rather than an end in itself, MA can support more relevant engagement and strengthen the translation of evidence into practice.
Identifiers
42446850What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.